GC Biopharma | Sustainability Performance
Develops, manufactures, and markets biopharmaceutical and vaccine products.
1967
South Korea
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5375
Overallⓘ#54
in South Koreaⓘ#116
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- GC Biopharma Corporation (formerly Green Cross), Korean blood products major, has faced multiple US FDA Form 483 observations at multiple production facilities including the contested historic 2023 enforcement actions on quality systems, plus periodic Korean FSC enforcement scrutiny on inadequate disclosure of US blood products customer concentration affecting institutional shareholders.
